Madrigal Pharmaceuticals Inc YDO1-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 7:55 PM CEST
72.00quote price arrow up+0.50 (+0.70%)
52 week range
70.50 - 115.60

...

Loading . . .
  • Open71.50
  • Day High72.50
  • Day Low70.50
  • Prev Close71.50
  • 52 Week High115.60
  • 52 Week High Date11/04/20
  • 52 Week Low70.50
  • 52 Week Low Date08/04/21

Key Stats

  • Market Cap1,402.64M
  • Shares Out16.06M
  • 10 Day Average Volume7.8
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-18.24

KEY STATS

  • Open71.50
  • Day High72.50
  • Day Low70.50
  • Prev Close71.50
  • 52 Week High115.60
  • 52 Week High Date11/04/20
  • 52 Week Low70.50
  • 52 Week Low Date08/04/21
  • Market Cap1,402.64M
  • Shares Out16.06M
  • 10 Day Average Volume7.8
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-18.24

RATIOS/PROFITABILITY

  • EPS (TTM)-11.99
  • P/E (TTM)-6.01
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Madrigal Pharmaceuticals Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and...
Paul Friedman M.D.
Chairman
Alex Howarth
Chief Financial Officer
Address
200 Barr Harbor Dr Ste 400
Conshohocken, PA
19428-2978
United States